Financial

News
Roche's Thomas Schinecker

Vabysmo vaults into Roche’s top growth spot

The undisputed star of Roche’s pharma portfolio in the first quarter of this year is eye disease therapy Vabysmo, heading for blockbuster territory after posting sales of